An engineered IL-2 partial agonist promotes CD8+ T cell stemness

Overview of attention for article published in Nature, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
blogs: 1 blog
twitter: 52 X users

patent: 3 patents
reddit: 1 Redditor
f1000: 1 research highlight platform

Citations

dimensions_citation: 95 Dimensions

Readers on

mendeley: 246 Mendeley

Summary News Blogs X Patents Reddit Research highlights Dimensions citations

So far, Altmetric has seen 2 news stories from 1 outlets.

CD8+ T 세포 줄기세포성을 촉진하는 조작된 IL-2 Partial agonist

Nature Asia , 06 Oct 2021

리서치 하이라이트 2021년9월15일 Nature 597, 7877 입양 세포 치료(Adoptive cell therapy)는 특정 유형의 암 환자에게 효과적인 치료법으로 부상하였다.

CD8+ T 세포 줄기세포성을 촉진하는 조작된 IL-2 Partial agonist(Nature)

Nature Asia , 22 Sep 2021

리서치 하이라이트 2021년9월15일 Nature 597, 7877 입양 세포 치료(Adoptive cell therapy)는 특정 유형의 암 환자에게 효과적인 치료법으로 부상하였다.